Runny nose

Calcium gluconate (tablets): instructions for use. Calcium gluconate Tablets: instructions, description PharmPrice Proper safety precautions for use

active ingredient: 1 tablet contains calcium gluconate in terms of 100% substance - 500 mg;

excipients: potato starch, croscarmellose sodium, talc, calcium stearate.

Dosage form

Pills.

Tablets are white, flat-cylindrical, scored and chamfered.

Manufacturer name and location

PJSC "Kievmedpreparat" Ukraine, 01032, Kyiv, st. Saksaganskogo, 139.

PJSC "Galichfarm", Ukraine, 79024, m. Lvov, st. Opryshkivska, 6/8.

Pharmacotherapeutic group

Calcium preparations. ATS code 12 A03.

Calcium gluconate is a calcium salt of gluconic acid, which contains 9% calcium. Calcium ions take part in the transmission of nerve impulses, the contraction of smooth and skeletal muscles, the functioning of the myocardium, and blood clotting processes; they are necessary for the formation of bone tissue and the normal functioning of other systems and organs. The concentration of calcium ions in the blood decreases in many pathological processes; Severe hypocalcemia contributes to the occurrence of tetany. Calcium gluconate, in addition to eliminating hypocalcemia, reduces vascular permeability, has antiallergic, anti-inflammatory, hemostatic effects, and also reduces exudation. Calcium ions are a plastic material for the skeleton and teeth, participate in various enzymatic processes, regulate the speed of nerve impulses and the permeability of cell membranes. Calcium ions are necessary for the process of neuromuscular transmission and to maintain the contractile function of the myocardium. Unlike calcium chloride, calcium gluconate has a weaker muscle irritant effect.

When taken orally, calcium gluconate is partially absorbed, mainly in the small intestine. The maximum concentration in blood plasma is achieved after 1.2-1.3 hours. The half-life of ionized calcium from blood plasma is 6.8-7.2 hours. Penetrates through the placental barrier and into breast milk. It is excreted from the body in urine and feces.

Indications for use

Diseases accompanied by hypocalcemia, increased permeability of cell membranes, and disruption of the conduction of nerve impulses in muscle tissue. Hypoparathyroidism (latent tetany, osteoporosis), vitamin D metabolism disorders (rickets, spasmophilia, osteomalacia), hyperphosphatemia in patients with chronic renal failure. Increased need for calcium (period of intensive growth in children and adolescents, pregnancy, breastfeeding), insufficient Ca 2+ in food, impaired calcium metabolism in the postmenopausal period, bone fractures. Increased excretion of Ca 2+ (prolonged bed rest, chronic diarrhea, hypocalcemia with long-term use of diuretics, antiepileptic drugs, glucocorticosteroids). In complex therapy: bleeding of various etiologies, allergic diseases (serum sickness, urticaria, febrile syndrome, itchy dermatoses, angioedema); bronchial asthma, dystrophic alimentary edema, pulmonary tuberculosis, eclampsia, parenchymal hepatitis, toxic liver damage, nephritis. Poisoning with magnesium salts, oxalic acid, soluble salts of fluoric acid (when interacting with calcium gluconate, insoluble and non-toxic calcium oxalate and calcium fluoride are formed).

Contraindications

Hypersensitivity to the components of the drug, hypercalcemia, severe hypercalciuria, hypercoagulation (increased blood clotting), tendency to thrombus formation, severe atherosclerosis, nephrourolithiasis (calcium), severe renal failure, sarcoidosis, taking digitalis drugs.

Proper safety precautions for use

When used in patients receiving cardiac glycosides and/or diuretics, as well as during long-term treatment, the concentration of calcium and creatinine in the blood should be monitored. If their concentration increases, the dose of the drug should be reduced or its use should be temporarily stopped. Due to the fact that vitamin D 3 increases the absorption of calcium from the gastrointestinal tract, in order to avoid an overdose of calcium, it is necessary to take into account the intake of vitamin D 3 and calcium from other sources.

Patients with mild hypercalciuria (more than 300 mg/day = 7.5 mmol/day), mild renal dysfunction, and a history of urolithiasis should be prescribed with caution and the level of urinary calcium excretion should be regularly monitored. If necessary, reduce the dose of the drug or discontinue it. Patients with a tendency to form stones in the urinary tract are advised to increase the volume of fluid consumed during treatment.

When treating with the drug, you should avoid taking high doses of vitamin D or its derivatives, unless there are special indications for this.

An interval of at least 3 hours should be maintained between taking calcium gluconate tablets and oral medications estramustine, etidronate and other bisphosphonates, phenytoin, quinolones, tetracycline antibiotics, oral iron supplements and fluoride supplements.

Use during pregnancy or breastfeeding

The use of the drug is permissible taking into account the ratio of benefit to the woman/risk to the fetus (child), which is determined by the doctor. When using calcium supplements during breastfeeding, it may pass into breast milk.

The ability to influence the reaction rate when driving a vehicle or working with other mechanisms

The drug does not affect the reaction rate when driving vehicles or working with complex mechanisms.

Children

The drug is used for children aged 3 years and older.

Directions for use and doses

Prescribed orally before meals. The tablet must be chewed or crushed.

For adults and children over 14 years of age, the drug is prescribed in a single dose of 1-3 g (2-6 tablets), for children aged 3 to 4 years - 1 g (2 tablets), from 5 to 6 years - 1-1. 5 g (2-3 tablets), from 7 to 9 years - 1.5-2 g (3-4 tablets), from 10 to 14 years - 2-3 g (4-6 tablets) 2-3 times per day. The daily dose for elderly patients should not exceed 2 g (4 tablets) per day.

The duration of treatment is determined by the doctor individually, depending on the patient’s condition.

Overdose

With long-term use in high doses, hypercalcemia with the deposition of calcium salts in the body is possible, and dyspepsia is possible. The likelihood of developing hypercalcemia increases with simultaneous treatment with high doses of vitamin D or its derivatives.

Symptoms of hypercalcemia: drowsiness, weakness, anorexia, abdominal pain, vomiting, nausea, constipation, polydipsia, polyuria, increased fatigue, irritability, poor health, depression, dehydration, possible heart rhythm disturbances, myalgia, arthralgia, arterial hypertension.

Treatment: drug withdrawal; in severe cases - parenteral calcitonin at a dose of 5-10 IU/kg body weight per day (diluted in 500 ml of sterile physiological sodium chloride solution, intravenously drip over 6 hours. Slow intravenous jet administration is possible 2-4 times a day).

Side effects

The drug is usually well tolerated, but sometimes disturbances are possible:

from the digestive tract: nausea, vomiting, diarrhea, pain in the epigastric region, constipation; with long-term use in high doses - the formation of calcium stones in the intestines;

from the cardiovascular system: bradycardia;

from the metabolic side: hypercalcemia, hypercalciuria;

from the urinary system: impaired renal function (frequent urination, swelling of the lower extremities).

Allergic reactions may occur.

These phenomena quickly disappear after reducing the dose or discontinuing the drug.

Interaction with other drugs and other types of interactions.

The drug slows down the absorption of estramustine, etidronate and other bisphosphonates, quinolones, tetracycline antibiotics, oral iron supplements and fluoride preparations (the interval between doses should be at least 3 hours). Calcium gluconate reduces the bioavailability of phenytoin. When taken simultaneously with vitamin D or its derivatives, calcium absorption increases. Cholesterolamine reduces calcium absorption in the digestive tract. When the drug is used together with cardiac glycosides, the cardiotoxic effects of the latter are enhanced. GCS reduce calcium absorption. When combined with thiazide diuretics, it may increase the risk of developing hypercalcemia. The drug may reduce the effect of calcitonin in hypercalcemia, the bioavailability of phenytoin, and the effect of calcium channel blockers. When used simultaneously with quinidine, intraventricular conduction may slow down and the toxicity of quinidine may increase.

Forms insoluble or slightly soluble calcium salts with carbonates, salicylates, and sulfates.

Calcium absorption from the gastrointestinal tract can be reduced by certain types of food (spinach, rhubarb, bran, grains).

Best before date

Storage conditions

Store in original packaging at a temperature not exceeding 25 ºС.

Keep out of the reach of children.

active ingredient: Salcium gluconate;

1 tablet contains calcium gluconate 500 mg;

excipients: potato starch, talc, calcium stearate.

Dosage form. Pills.

Basic physical and chemical properties: solid, regular, round cylinders, the upper and lower surfaces of which are flat, the edges of the surfaces are beveled, with a mark for dividing, white. Marbling is allowed on the surface of the tablets.

Pharmacotherapeutic group.

Mineral supplements. Calcium preparations. ATX code A12A A03.

Pharmacological properties

Pharmacodynamics.

Calcium gluconate is a calcium salt of gluconic acid containing 9% calcium. Calcium ions are involved in the transmission of nerve impulses, the contraction of smooth and skeletal muscles, the functioning of the myocardium, and blood clotting processes; they are necessary for the formation of bone tissue and the normal functioning of other systems and organs. The concentration of calcium ions in the blood decreases in many pathological processes; Severe hypocalcemia contributes to the occurrence of tetany. Calcium gluconate, in addition to eliminating hypocalcemia, reduces vascular permeability, has antiallergic, anti-inflammatory, hemostatic effects, and also reduces exudation. Calcium ions are a plastic material for the skeleton and teeth, participate in various enzymatic processes, regulate the speed of nerve impulses and the permeability of cell membranes. Calcium ions are necessary for the process of neuromuscular transmission and to maintain the contractile function of the myocardium. Unlike calcium chloride, calcium gluconate has a weaker local irritant effect.

Pharmacokinetics.

When taken orally, calcium gluconate is partially absorbed mainly in the small intestine. The maximum concentration in blood plasma is achieved after 1.2-1.3 hours. The half-life of ionized calcium from blood plasma is 6.8-7.2 hours. Penetrates the placental barrier and is excreted into breast milk. It is excreted from the body in urine and feces.

Clinical characteristics.

Indications.

Increased need for calcium (period of intensive growth of children and adolescents, pregnancy or breastfeeding), insufficient Ca 2+ content in food, disturbance of its metabolism in the postmenopausal period, bone fractures. Increased excretion of Ca 2+ (prolonged bed rest, chronic diarrhea, hypocalcemia with long-term use of diuretics, antiepileptic drugs, glucocorticosteroids). In complex therapy: bleeding of various etiologies, allergic diseases (serum sickness, urticaria, febrile syndrome, itchy dermatoses, angioedema); bronchial asthma, dystrophic alimentary edema, pulmonary tuberculosis, eclampsia, parenchymal hepatitis, toxic liver damage, nephritis. As an antidote for poisoning with magnesium salts, oxalic acid, soluble salts of fluoric acid (when interacting with calcium gluconate, insoluble and non-toxic calcium oxalate and calcium fluoride are formed).

Contraindications

Hypersensitivity to the components of the drug. Hypercalcemia, severe hypercalciuria, hypercoagulation, tendency to thrombus formation, severe atherosclerosis, increased blood clotting, nephrourolithiasis (calcium), severe renal failure, sarcoidosis, taking digitalis drugs.

Interaction with other drugs and other types of interactions.

The drug slows down the absorption of estramustine, etidronate and other bisphosphonates, quinolones, tetracycline antibiotics, oral iron supplements and fluoride preparations (the interval between doses should be at least 3 hours). Calcium gluconate reduces the bioavailability of phenytoin. When taken simultaneously with vitamin D or its derivatives, calcium absorption increases. Cholesterolamine reduces calcium absorption in the digestive tract. When the drug is used together with cardiac glycosides, the cardiotoxic effects of the latter are enhanced. Glucocorticosteroids reduce calcium absorption. When combined with thiazide diuretics, the risk of hypercalcemia may increase. The drug may reduce the effect of calcitonin in hypercalcemia, the bioavailability of phenytoin, and the effect of calcium channel blockers. When used simultaneously with quinidine, intraventricular conduction may slow down and the toxicity of quinidine may increase.

Forms insoluble or slightly soluble calcium salts with carbonates, salicylates, and sulfates.

Calcium absorption from the digestive tract can be reduced by some types of food (spinach, rhubarb, bran, grains).

Features of application

When used in patients receiving cardiac glycosides and/or diuretics, as well as during long-term treatment, the concentration of calcium and creatinine in the blood should be monitored. If their concentration increases, you need to reduce the dose of the drug or temporarily stop using it. Due to the fact that vitamin D 3 increases the absorption of calcium from the digestive tract, in order to avoid an overdose of calcium, it is necessary to take into account the intake of vitamin D 3 and calcium from other sources.

With caution and with regular monitoring of the level of calcium excretion in the urine, it is prescribed to patients with moderate hypercalciuria exceeding 300 mg/day (7.5 mmol/day), mildly expressed renal dysfunction, and a history of urolithiasis. If necessary, you need to reduce the dose of the drug or discontinue it. Patients with a tendency to form stones in the urinary tract are advised to increase the volume of fluid consumed during treatment.

When treating with the drug, you should avoid taking high doses of vitamin D or its derivatives, unless there are special indications for this.

It is necessary to maintain an interval of at least 3 hours between taking calcium gluconate and oral medications estramustine, etidronate and other bisphosphonates, phenytoin, quinolones, tetracycline antibiotics, oral iron supplements and fluoride preparations.

Use during pregnancy or breastfeeding.

The use of the drug is permissible taking into account the ratio of benefit for the woman/risk for the fetus/child, which is determined by the doctor.

When taking calcium supplements during breastfeeding, it may pass into breast milk.

The ability to influence the reaction rate when driving vehicles or other mechanisms.

No effect.

Directions for use and doses

Administer orally before meals. The tablet must be chewed or crushed.

For adults and children over 14 years of age, the drug should be prescribed in a single dose of 1-3 g (2-6 tablets), for children from 3 to 4 years old - 1 g (2 tablets), from 5 to 6 years old - 1-1.5 g. (2-3 tablets), from 7 to 9 years – 1.5-2 g (3-4 tablets), from 10 to 14 years – 2-3 g (4-6 tablets) 2-3 times a day .

The daily dose for elderly patients should not exceed 2 g (4 tablets).

The duration of treatment is determined by the doctor individually depending on the patient’s condition.

Children.

The drug should be used in children over 3 years of age.

Overdose

With long-term use in high doses, hypercalcemia with the deposition of calcium salts in the body is possible, and dyspeptic symptoms are possible. The likelihood of developing hypercalcemia increases with simultaneous treatment with high doses of vitamin D or its derivatives.

Symptoms of hypercalcemia: drowsiness, weakness, anorexia, abdominal pain, vomiting, nausea, constipation, polydipsia, polyuria, weakness, increased fatigue, irritability, poor health, depression, dehydration, possible heart rhythm disturbances, myalgia, arthralgia, arterial hypertension.

Treatment: drug withdrawal; in severe cases - parenteral calcitonin at a dose of 5-10 IU/kg body weight per day (diluted in 500 ml of 0.9% sodium chloride solution), intravenously drip for 6 hours. Possible intravenous jet slow administration 2-4 times a day.

Adverse reactions

Usually the drug is well tolerated, but sometimes allergic reactions and other disorders are possible:

from the digestive tract: nausea, vomiting, diarrhea, abdominal pain, constipation; with long-term use in high doses – the formation of calcium stones in the intestines;

from the cardiovascular system: bradycardia;

on the metabolic side: hypercalcemia, hypercalciuria;

from the urinary system: impaired renal function (increased urination, swelling of the lower extremities).

These phenomena quickly disappear after reducing the dose or discontinuing the drug.

Best before date

Storage conditions

Store in original packaging at a temperature not exceeding 25 °C.

Keep out of the reach of children.

Package

10 tablets in blisters.

Manufacturer.

JSC "Lubnyfarm"

The location of the manufacturer and the address of the place of its activities.

Ukraine, 37500, Poltava region, Lubny, st. Barvinkova, 16.

Compound

1 tablet contains the active substance: calcium gluconate monohydrate - 500.0 mg.

Pharmacotherapeutic group

Calcium-phosphorus metabolism regulator

ATX code

Pharmacological action

The calcium preparation replenishes the deficiency of calcium ions necessary for the transmission of nerve impulses, contraction of skeletal and smooth muscles, myocardial activity, bone tissue formation, and blood clotting.

Indications for use

Diseases accompanied by hypocalcemia, increased permeability of cell membranes (including blood vessels), disruption of the conduction of nerve impulses in muscle tissue. Hypoparathyroidism (latent tetany, osteoporosis), vitamin D metabolism disorders: rickets (spasmophilia, osteomalacia), hyperphosphatemia in patients with chronic renal failure. Increased need for calcium ions (pregnancy, breastfeeding, periods of increased body growth), insufficient calcium ions in food, disturbances in its metabolism (in the postmenopausal period). Enhanced excretion of calcium ions (prolonged bed rest, chronic diarrhea, secondary hypocalcemia due to long-term use of diuretics and antiepileptic drugs, glucocorticosteroids). Poisoning with magnesium salts, oxalic and hydrofluoric acids and their soluble salts (when interacting with calcium gluconate, insoluble and non-toxic calcium oxalate and calcium fluoride are formed). Hyperkalemic form of paroxysmal myoplegia.

Contraindications

Hypersensitivity to the components of the drug, hypercalcemia (calcium concentration should not exceed 12 mg% or 6 mEq/l), severe hypercalciuria, nephrourolithiasis (calcium), severe renal failure, sarcoidosis, concomitant use of cardiac glycosides (risk of arrhythmias), children up to 3 years.

Directions for use and doses

The tablet should be swallowed whole, without chewing, with a small amount of water. It is advisable to take the drug at the same time of day, regardless of meal times. Adults and adolescents over 12 years of age - 1 tablet (5 mg) 1 time per day.

Release form

Tablets 500 mg. 10 tablets in a blister pack made of polyvinyl chloride film and printed varnished aluminum foil. 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 tablets in polymer jars for medicines. One can or 1, 2, 3.4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 strip packaging along with instructions for use are placed in cardboard packaging (pack).

Release form

Pills

Compound

1 tab. calcium gluconate monohydrate 500 mg. Excipients: potato starch 23 mg, talc 5 mg, calcium stearate monohydrate 2 mg.

Pharmacological effect

The calcium supplement replenishes the deficiency of calcium ions necessary for the transmission of nerve impulses, contraction of skeletal and smooth muscles, myocardial activity, bone tissue formation, and blood clotting.

Pharmacokinetics

Approximately 1/5-1/3 of the orally administered drug is absorbed in the small intestine; this process depends on the presence of vitamin D, pH, diet and the presence of factors that can bind calcium ions. The absorption of calcium ions increases with calcium deficiency and the use of a diet with a reduced content of calcium ions. About 20% is excreted by the kidneys, the remaining amount (80%) is removed with the contents of the intestine.

Indications

Diseases accompanied by hypocalcemia, increased permeability of cell membranes (including blood vessels), disruption of the conduction of nerve impulses in muscle tissue. Hypoparathyroidism (latent tetany, osteoporosis), vitamin D metabolism disorders: rickets (spasmophilia, osteomalacia), hyperphosphatemia in patients with chronic renal failure. Increased need for calcium ions (pregnancy, lactation, period of increased growth of the body), insufficient content of calcium ions in food, disturbance of its metabolism (in the postmenopausal period). Enhanced excretion of calcium ions (prolonged bed rest, chronic diarrhea, secondary hypocalcemia due to long-term use of diuretics and antiepileptic drugs, glucocorticosteroids). Poisoning with salts of magnesium ions, oxalic and fluoric acids and their soluble salts (when interacting with calcium gluconate, insoluble and non-toxic calcium oxalate and calcium fluoride are formed). Hypercalcemic form of paroxysmal myoplegia.

Contraindications

Hypersensitivity, hypercalcemia (the concentration of calcium ions should not exceed 12 mg% ~ 6 mEq/l), severe hypercalciuria, nephrourolithiasis (calcium), sarcoidosis, concomitant use of cardiac glycosides (risk of arrhythmias), children under 3 years of age. With caution. Dehydration, electrolyte disturbances (risk of developing hypercalcemia), diarrhea, malabsorption syndrome, slight hypercalciuria, moderate chronic renal failure, chronic heart failure, widespread atherosclerosis, hypercoagulation, calcium nephrourolithiasis (history).

Use during pregnancy and breastfeeding

Application is possible according to the dosage regimen.

Directions for use and doses

Grind before use. Orally, before meals or 1-1.5 hours after consumption (with milk). Adults - 1-3 g 2-3 times a day (maximum daily dose - 9 g). Pregnant and nursing mothers - 1-3 g 2-3 times a day (maximum daily dose - 9 g). Children: 3-4 years old - 1 g (maximum daily dose - 3.0 g); 5-6 years - 1-1.5 g (maximum daily dose - 4.5 g); 7-9 years – 1.5-2 g (maximum daily dose - 6 g); 10-14 years - 2-3 g (maximum daily dose - 9 g); frequency of administration - 2-3 times a day.

Side effects

Constipation, irritation of the gastrointestinal mucosa, hypercalcemia.

Overdose

Symptoms: development of hypercalcemia. Treatment: calcitonin is administered 5-10 IU/kg/day. (diluted in 500 ml of 0.9% sodium chloride solution). Duration of administration 6 hours.

Interaction with other drugs

Forms insoluble complexes with tetracycline antibiotics (reduces the antibacterial effect). When used simultaneously with quinidine, intraventricular conduction may slow down and the toxicity of quinidine may increase. Slows down the absorption of tetracyclines, digoxin, and oral iron supplements (the interval between doses should be at least 2 hours). When combined with thiazide diuretics, it may increase hypercalcemia. Reduces the effect of calcitonin in hypercalcemia. Reduces the bioavailability of phenytoin.

Special instructions

In patients with mild hypercalciuria, decreased glomerular filtration, or a history of nephrourolithiasis, treatment should be carried out under the control of the concentration of calcium ions in the urine. To reduce the risk of developing nephrourolithiasis, drinking plenty of fluids is recommended.

Instructions for use of dietary supplement

Calcium gluconate 500 mg

Source of calcium

How the ingredients work

Calcium. The physiological significance of calcium in the body is diverse. It is part of the main mineral component of bone tissue - oxyapatite, whose microcrystals form the rigid structure of bone tissue. Calcium ions impart stability to cell membranes by forming bonds between negatively charged groups of phospholipids, structural proteins and glycoproteins. Calcium plays an important role in intercellular interactions, which ensure ordered adhesion (cell adhesion) during tissue formation.

Along with plastic and structural functions, calcium plays a decisive role in many physiological and biochemical processes: it is necessary for normal excitability of the nervous system and muscle contractility, is an activator of a number of enzymes and hormones, and is also an essential component of the blood coagulation system.

Compound

calcium gluconate, corn starch (carrier), vegetable calcium stearate and amorphous silicon dioxide (anti-caking agents).

Adults and children over 14 years old - 2 tablets 2 times a day with meals. Duration of treatment is 1-2 months. If necessary, the reception can be repeated.

Contraindications

Persons with individual intolerance to the product, pregnant or breastfeeding women. It is recommended to consult a doctor before use.

Release form

Pills

Number of tablets per package

20, 120 tablets, 0.53 g each

Best before date

Storage conditions

Store at a temperature not exceeding 25°C

Manufacturer